Two/CD
distinct/JJ
signal/NN
transmission/NN
pathways/NNS
in/IN
T/NN
lymphocytes/NNS
are/VBP
inhibited/VBN
by/IN
complexes/NNS
formed/VBN
between/IN
an/DT
immunophilin/NN
and/CC
either/CC
FK506/NN
or/CC
rapamycin/NN
./.

Proliferation/NN
and/CC
immunologic/JJ
function/NN
of/IN
T/NN
lymphocytes/NNS
are/VBP
initiated/VBN
by/IN
signals/NNS
from/IN
the/DT
antigen/NN
receptor/NN
that/WDT
are/VBP
inhibited/VBN
by/IN
the/DT
immunosuppressant/JJ
FK506/NN
but/CC
not/RB
by/IN
its/PRP$
structural/JJ
analog/NN
,/,
rapamycin/NN
./.
=====
On/IN
the/DT
other/JJ
hand/NN
,/,
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
-induced/JJ
signals/NNS
are/VBP
blocked/VBN
by/IN
rapamycin/NN
but/CC
not/RB
by/IN
FK506/NN
./.
=====
Remarkably/RB
,/,
these/DT
two/CD
drugs/NNS
inhibit/VBP
each/DT
other/JJ
's/POS
actions/NNS
,/,
raising/VBG
the/DT
possibility/NN
that/IN
both/DT
act/VBP
by/IN
means/NNS
of/IN
a/DT
common/JJ
immunophilin/NN
(/(
immunosuppressant/JJ
binding/NN
protein/NN
)/)
./.
=====
We/PRP
find/VBP
that/IN
the/DT
dissociation/NN
constant/NN
of/IN
rapamycin/NN
to/TO
the/DT
FK506/NN
binding/NN
protein/NN
FKBP/NN
(/(
Kd/NN
=/JJ
0.2/CD
nM/NN
)/)
is/VBZ
close/JJ
to/TO
the/DT
dissociation/NN
constant/NN
of/IN
FK506/NN
to/TO
FKBP/NN
(/(
Kd/NN
=/JJ
0.4/CD
nM/NN
)/)
and/CC
to/TO
their/PRP$
effective/JJ
biologic/JJ
inhibitory/JJ
concentrations/NNS
./.
=====
However/RB
,/,
an/DT
excess/NN
of/IN
rapamycin/NN
is/VBZ
needed/VBN
to/TO
revert/VB
FK506-mediated/JJ
inhibition/NN
of/IN
IL-2/NN
production/NN
,/,
apoptosis/NN
,/,
and/CC
transcriptional/JJ
activation/NN
of/IN
NF-AT/NN
,/,
a/DT
T-cell-specific/JJ
transcription/NN
factor/NN
necessary/JJ
for/IN
IL-2/NN
gene/NN
activation/NN
./.
=====
Similarly/RB
,/,
an/DT
excess/NN
of/IN
FK506/NN
is/VBZ
needed/VBN
to/TO
revert/VB
rapamycin-mediated/JJ
inhibition/NN
of/IN
IL-2-induced/JJ
proliferation/NN
./.
=====
The/DT
drug/NN
concentrations/NNS
required/VBN
for/IN
antagonism/NN
may/MD
be/VB
explained/VBN
by/IN
the/DT
relative/JJ
affinity/NN
of/IN
the/DT
drugs/NNS
to/TO
,/,
and/CC
by/IN
the/DT
abundance/NN
of/IN
,/,
the/DT
immunophilin/NN
FKBP/NN
./.
=====
FKBP/NN
has/VBZ
been/VBN
shown/VBN
to/TO
catalyze/VB
the/DT
interconversion/NN
of/IN
the/DT
cis-/JJ
and/CC
trans-rotamers/NNS
of/IN
the/DT
peptidyl-prolyl/JJ
amide/NN
bond/NN
of/IN
peptide/NN
substrates/NNS
;/:
here/RB
we/PRP
show/VBP
that/IN
rapamycin/NN
,/,
like/IN
FK506/NN
,/,
is/VBZ
a/DT
potent/JJ
inhibitor/NN
of/IN
the/DT
rotamase/NN
activity/NN
of/IN
FKBP/NN
(/(
Ki/NN
=/JJ
0.2/CD
nM/NN
)/)
./.
=====
Neither/CC
FKBP/NN
binding/NN
nor/CC
inhibition/NN
of/IN
rotamase/NN
activity/NN
of/IN
FKBP/NN
alone/RB
is/VBZ
sufficient/JJ
to/TO
explain/VB
the/DT
biologic/JJ
actions/NNS
of/IN
these/DT
drugs/NNS
./.
=====
Rather/RB
,/,
these/DT
findings/NNS
suggest/VBP
that/IN
immunophilin/NN
bound/VBN
to/TO
FK506/NN
interferes/VBZ
with/IN
antigen/NN
receptor-induced/JJ
signals/NNS
,/,
while/IN
rapamycin/NN
bound/VBN
to/TO
the/DT
immunophilin/NN
interferes/VBZ
with/IN
IL-2-induced/JJ
signals/NNS
./.